Are the Patients Having Pets at Greater Risk of Carrying Multidrug Resistance Bacteriae? (BRANITRANS)

December 13, 2019 updated by: CHU de Reims

Introduction : The multidrug resistance (MDR) Bacteriae are growing and are a public health problem. The known risk factors to be expanding of MDR Bacteriae are: taken antibiotics, hospitalization, journey in a country at risk. Other risk factors are emitted in hypothesis as the presence of pets.

Aim : The primary objective is to study the association between the presence of a pet and the presence of a MDR bacteria. Methods : Cross sectional study will be performed in Reims University hospital in internal medicine ward.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Introduction : The multidrug resistance (MDR) Bacteriae are growing and are a public health problem. The known risk factors to be expanding of MDR Bacteriae are: taken antibiotics, hospitalization, journey in a country at risk. Other risk factors are emitted in hypothesis as the presence of pets.

Aim : The primary objective is to study the association between the presence of a pet and the presence of a MDR bacteria.

Methods : Cross sectional study will be performed in Reims University hospital in internal medicine ward. Within the framework of the management of patients in internal medicine ward, all the hospitalized patients have systematically a screening of MDR Bacteriae. A questionnaire will be put handed to all the patients during their hospitalization as soon as they will be able to answer it. They will be informed about the objectives of the study. If the patient agrees to participate in the study, the questionnaire will be filled by every patient. It includes essentially closed questions and some open questions. A descriptive analysis will be performed. Bivariate analysis will be performed to investigate the relation between the presence of a pet and the presence of a MDR bacteria and clinical variables Multivariate logistic regression will be performed to investigate the factors independently related to the presence of a MDR bacteria.

Study Type

Observational

Enrollment (Anticipated)

900

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Reims, France, 51092
        • Recruiting
        • CHU Reims

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients hospitalized in internal medicine ward of Reims University hospital

Description

Inclusion Criteria:

  • Patients who were screened for MDR bacteria
  • Patients who accepted to participate in the study
  • >18yo

exclusion criteria :

  • Patient hospitalized before admission in our ward and having acquired a MDR bacteria in the course of care.
  • Patients coming from nursing home or institutionalized patients
  • Patient who cannot communicated

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Crossover
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients hospitalized in internal medicine ward
Patients included are patients hospitalized in internal medicine ward.
Other: Screening of MDR Bacteriae
questionnaire will be filled by every patient

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Association between the presence of a pet and the presence of a MDR bacteria
Time Frame: Day0
Day0

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

CHU de Reims

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 12, 2017

Primary Completion (Anticipated)

June 11, 2024

Study Completion (Anticipated)

January 1, 2025

Study Registration Dates

First Submitted

November 17, 2017

First Submitted That Met QC Criteria

November 22, 2017

First Posted (Actual)

November 24, 2017

Study Record Updates

Last Update Posted (Actual)

December 16, 2019

Last Update Submitted That Met QC Criteria

December 13, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • PO17041

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multidrug Resistance

Clinical Trials on Screening of MDR Bacteriae

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe